Questcor Pharmaceuticals Inc (NASDAQ:QCOR) investors: listen up.
In today’s marketplace, there are a multitude of methods shareholders can use to watch stocks. A pair of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top hedge fund managers can beat their index-focused peers by a healthy margin (see just how much).
Just as necessary, bullish insider trading sentiment is a second way to analyze the investments you’re interested in. Just as you’d expect, there are a number of stimuli for a corporate insider to sell shares of his or her company, but only one, very clear reason why they would buy. Many academic studies have demonstrated the useful potential of this method if you understand what to do (learn more here).
What’s more, we’re going to study the latest info for Questcor Pharmaceuticals Inc (NASDAQ:QCOR).
How have hedgies been trading Questcor Pharmaceuticals Inc (NASDAQ:QCOR)?
In preparation for the third quarter, a total of 27 of the hedge funds we track were bullish in this stock, a change of 4% from one quarter earlier. With hedgies’ sentiment swirling, there exists a select group of notable hedge fund managers who were upping their stakes meaningfully.
According to our 13F database, Broadwood Capital, managed by Neal C. Bradsher, holds the biggest position in Questcor Pharmaceuticals Inc (NASDAQ:QCOR). Broadwood Capital has a $149.8 million position in the stock, comprising 34.1% of its 13F portfolio. On Broadwood Capital’s heels is Christopher R. Hansen of Valiant Capital, with a $41.5 million position; 5% of its 13F portfolio is allocated to the stock. Remaining hedge funds with similar optimism include Jim Simons’s Renaissance Technologies, William Leland Edwards’s Palo Alto Investors and Phill Gross and Robert Atchinson’s Adage Capital Management.
Consequently, particular hedge funds have been driving this bullishness. Broadwood Capital, managed by Neal C. Bradsher, created the biggest position in Questcor Pharmaceuticals Inc (NASDAQ:QCOR). Broadwood Capital had 149.8 million invested in the company at the end of the quarter. Christopher R. Hansen’s Valiant Capital also initiated a $41.5 million position during the quarter. The other funds with brand new QCOR positions are Jim Simons’s Renaissance Technologies, William Leland Edwards’s Palo Alto Investors, and Phill Gross and Robert Atchinson’s Adage Capital Management.
How have insiders been trading Questcor Pharmaceuticals Inc (NASDAQ:QCOR)?
Insider buying made by high-level executives is best served when the company in question has seen transactions within the past half-year. Over the latest 180-day time frame, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).
We’ll also take a look at the relationship between both of these indicators in other stocks similar to Questcor Pharmaceuticals Inc (NASDAQ:QCOR). These stocks are Theravance Inc (NASDAQ:THRX), Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Viropharma Inc (NASDAQ:VPHM), Charles River Laboratories (NYSE:CRL), and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). This group of stocks are in the biotechnology industry and their market caps match QCOR’s market cap.
| Company Name | # of Hedge Funds | # of Insiders Buying | # of Insiders Selling |
| Theravance Inc (NASDAQ:THRX) | 24 | 0 | 0 |
| Infinity Pharmaceuticals Inc. (NASDAQ:INFI) | 20 | 0 | 0 |
| Viropharma Inc (NASDAQ:VPHM) | 22 | 0 | 0 |
| Charles River Laboratories (NYSE:CRL) | 19 | 0 | 0 |
| Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) | 11 | 0 | 0 |
Using the returns explained by the previously mentioned strategies, average investors should always track hedge fund and insider trading activity, and Questcor Pharmaceuticals Inc (NASDAQ:QCOR) is no exception.
